Covid-19 roundup: Researchers claim trial success for Roche's Actemra as Alexion jumps in; Pfizer gambling $500M on an ambitious campaign
After Regeneron announced a setback on Monday with its research on the use of Kevzara in fighting the pandemic, hopes for the anti-inflammatory IL-6 class waned considerably. But now a group of researchers in France are cheering on a win in a controlled, randomized study of Roche’s rival Actemra, which has the same mode of action. And Roche cited it as part of the case for this drug as they push through their own Phase III.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.